Free Access: Overcoming the roadblocks in HCV, Facts and fictions of HCV and comorbidities and More....

Good morning folks, looking to catch up on some HCV reading? The Journal of Hepatology is open access this month, check out the highlights below, in addition download EASL Recommendations on Treatment of Hepatitis C 2014.

Journal of Hepatology

Vol. 61 Iss. 5, November 2014

This state-of-the-art collection has been produced by leading experts in the field covering all the important aspects of hepatitis C.

Twenty-five years following the discovery of the hepatitis C virus, the Journal of Hepatology brings you a comprehensive overview of the milestones in basic science and clinical developments and highlights the remaining challenges in the prevention and treatment of HCV infection.

Editorial

Overcoming the roadblocks in hepatitis C virus infection

Thomas F. Baumert, Stefan Zeuzem

S1–S2

PreviewAbstractFull-Text HTMLPDF

Basic

Virology and cell biology of the hepatitis C virus life cycle – An update

Jean Dubuisson, François-Loïc Cosset

S3–S13

PreviewAbstractFull-Text HTMLPDF

Innate and adaptive immune responses in HCV infections

Markus H. Heim, Robert Thimme

S14–S25

PreviewAbstractFull-Text HTMLPDF

HCV animal models and liver disease

Koen Vercauteren, Ype P. de Jong, Philip Meuleman

S26–S33

PreviewAbstractFull-Text HTMLPDF

A prophylactic hepatitis C virus vaccine: A distant peak still worth climbing

Thomas F. Baumert, Catherine Fauvelle, Diana Y. Chen, Georg M. Lauer

S34–S44

PreviewAbstractFull-Text HTMLPDF

Clinical Course

Global epidemiology and genotype distribution of the hepatitis C virus infection

Erin Gower, Chris Estes, Sarah Blach, Kathryn Razavi-Shearer, Homie Razavi

S45–S57

Published online: July 30, 2014

PreviewAbstractFull-Text HTMLPDFSupplemental Materials

Natural history of hepatitis C

Rachel H. Westbrook, Geoffrey Dusheiko

S58–S68

PreviewAbstractFull-Text HTMLPDF

Facts and fictions of HCV and comorbidities: Steatosis, diabetes mellitus, and cardiovascular diseases

Francesco Negro

S69–S78

PreviewAbstractFull-Text HTMLPDF

Pathogenesis and prevention of hepatitis C virus-induced hepatocellular carcinoma

Yujin Hoshida, Bryan C. Fuchs, Nabeel Bardeesy, Thomas F. Baumert, Raymond T. Chung

S79–S90

PreviewAbstractFull-Text HTMLPDF

Treatment

Antiviral therapy with nucleotide polymerase inhibitors for chronic hepatitis C

Sonal Kumar, Ira M. Jacobson

S91–S97

PreviewAbstractFull-Text HTMLPDF

Interferon-free antiviral combination therapies without nucleosidic polymerase inhibitors

Tania Mara Welzel, Georg Dultz, Stefan Zeuzem

S98–S107

PreviewAbstractFull-Text HTMLPDF

Management of acute and chronic HCV infection in persons with HIV coinfection

Mark S. Sulkowski

S108–S119

PreviewAbstractFull-Text HTMLPDF

Treatment options in patients with decompensated cirrhosis, pre- and post-transplantation

Martina Gambato, Sabela Lens, Miquel Navasa, Xavier Forns

S120–S131

PreviewAbstractFull-Text HTMLPDFSupplemental Materials

Simplification of antiviral hepatitis C virus therapy to support expanded access in resource-limited settings

Nathan Ford, Tracy Swan, Peter Beyer, Gottfried Hirnschall, Philippa Easterbrook, Stefan Wiktor

S132–S138

PreviewAbstractFull-Text HTMLPDF

2015 Upcoming Events

IBC

AbstractPDF

The 2015 International Liver Congress

OBC

AbstractPDF

Just In - Video:EASL Recommendations on Treatment of Hepatitis C, 2014

Watch - EASL Recommendations on Treatment of Hepatitis C, 2014 

Uploaded May 7  EASLEurope

HCV recommendations presented by Prof. Jean-Michel Pawlotsky at the International Liver Congress™ 2014, London, are now publicly available for the benefit of all.

In April the European Medicines Agency (EMA) released new recommendations on the treatment of hepatitis C at the EASL International Liver Congress 2014 meeting, in addition the World Health Organization (WHO) issued its first guidance for the treatment of hepatitis C as well.

EASL: An interview with Jean-Michel Pawlotsky

An interview with Jean-Michel Pawlotsky, Former EASL Secretary General, who led the consolidation of the new EASL treatment guidelines for hepatitis C launched at The International Liver CongressTM 2014.

The World Health Organization (WHO) issued its first guidance for the treatment of hepatitis C earlier this week.

Read more here....... 

Download - EASL Recommendations on Treatment of Hepatitis C 2014

EASL Recommendations on Treatment of Hepatitis C 2014

New guidelines for hepatitis C by European Medicines Agency (EMA) was released today at the EASL International Liver Congress 2014 meeting, the World Health Organization (WHO) issued its first guidance for the treatment of hepatitis C earlier this week.

According to an article published yesterday at Medscape Medical News; Jean-Michel Pawlotsky, MD, PhD, director of the French National Reference Centre for Viral Hepatitis stated that this new EASL document constitutes recommendations rather than guidelines because of the need to circumvent the traditional long guideline development process, which "doesn't fit the HCV field any longer."

In addition, Dr. Stefan Z. Wiktor noted both documents are expected to be revised soon. "It's such a rapidly moving field that, even as we were developing the guidelines, we had to modify our schedule to include recommendations on the newest drugs,"

EASL Recommendations on Treatment of Hepatitis C 2014
Hepatitis C virus (HCV) infection is one of the main causes of chronic liver disease worldwide. The long-term impact of HCV infection is highly variable, ranging from minimal histological changes to extensive fibrosis and cirrhosis with or without hepatocellular carcinoma (HCC)
(read more by viewing or downloading EASL recommendations)
 
Full version:  
EASL Recommendations on Treatment of Hepatitis C 2014
(download pdf)

Summary:
EASL Recommendations on Treatment of Hepatitis C 2014(download pdf)